Influenza virus vaccine (GlaxoSmithKline)
- Generic Name
- Influenza virus vaccine (GlaxoSmithKline)
Vaccine Responses in Patients With B Cell Malignancies
Phase 4
Recruiting
- Conditions
- Lymphoma
- Interventions
- Biological: Heplisav -BBiological: Pfizer-COVID-19 VaccineBiological: FluLavalDrug: AREXVY, ABRYSVO
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 500
- Registration Number
- NCT05170399
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 180
- Registration Number
- NCT03339713
- Locations
- 🇺🇸
Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath